تجاوز إلى المحتوى الرئيسي

بحث

عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) AstraZeneca Ongoing Lenvatinib (Lenvima) + Durvalumab (Imfinzi) + Tremelimumab (Imjudo) 3 D910VC00001 King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh)
A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) AstraZeneca Ongoing Tozorakimab (MEDI3506) 3 D9185C00001 King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh)
Non-Interventional Study of the Change in Joint Health in Adult Patients with Haemophilia A after Switching to Prophylaxis with Turoctocog Alfa Pegol (N8-GP) NovoNordisk Ongoing Turoctocog Alfa Pegol (N8-GP) 4 NN7088-492 King Abdulaziz University Hospital (Jeddah),King Fahad Hospital (Jeddah)
Assessment of Quality of Life in Patients with Relapsing Multiple Sclerosis treated with Cladribine tablets in the Kingdom of Saudi Arabia King Fahad Medical City Ongoing Cladribine 4 MS700568-2 King Fahad Medical City (Riyadh),King Saud Medical City (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah),King Faisal Specialist Hospital and Research Center (Jeddah),Dallah Hospital (Riyadh),King Fahd Armed Forces Hospital (Jeddah),King Fahd Military Medical Complex (Dhahran), Prince Sultan Military Medical City (Riyadh)
A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen Biogen Idec Research Limited Ongoing Nusinersen (Spinraza) 3 232SM302 King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam),King Abdulaziz Medical City NG (Jeddah)
A randomized double-blind placebo-controlled parallel group study assessing the efficacy and safety of dupilumab in patients with Allergic Fungal Rhinosinusitis (AFRS) Sanofi Ongoing Dupilumab 3 EFC16724 King Khalid University Hospital (Riyadh),King Faisal Specialist Hospital and Research Center (Riyadh)
Treatment of Cardio Vascular Disease with low dose Rivaroxaban in Advanced Chronic Kidney Disease(TRACK) KAIMRC Ongoing Rivaroxaban 3 SCT21R/008/10 King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah),King Khalid University Hospital (Riyadh)
A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE Pfizer Completed PF-06651600 2a B7981007 NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Boehringer Ingelheim Middle East & North Africa Ongoing BI 1015550 3 1305-0023 King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz University Hospital (Jeddah),King Fahad Specialist Hospital (Dammam)
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST) Biogen Idec Research Limited Ongoing BIIB059 2/3 230LE301 King Faisal Specialist Hospital and Research Center (Riyadh) , King Khalid University Hospital (Riyadh)
عرض 81 - 90 من 453